Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities. Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMab? mice), and in vivo/in vitro preclinical validation studies. Biocytogen collaborates with more than 70% of the top 50 pharmaceutical and biotechnology companies worldwide. Together, we discover innovative medicines for a better, healthier world.
Biocytogen的外部链接
?? AI + Biotech = The Future of Medicine! ???? ?? From designing new drugs to predicting diseases before they strike, AI is revolutionizing biotech faster than ever! But which breakthrough excites YOU the most? Cast your vote and let’s see where the future is headed! ?? Drop a comment if you have a bold AI + biotech prediction! ???? #AI #Biotech #Innovation #Biocytogen
此处无法显示此内容
在领英 APP 中访问此内容等
??Atopic Dermatitis Disease Models with Target-Humanized Mice ?? Atopic dermatitis (AD) is a chronic inflammatory skin condition affecting millions worldwide. It is primarily driven by type 2 inflammation and characterized by elevated Th2 cytokines such as IL-4, IL-13, and IL-31. TSLP, released by epithelial cells in response to allergens and microbes, promotes type 2 immune responses, contributing to chronic itching and inflammation. Despite AD’s widespread impact, effective treatments remain limited, highlighting the need for innovative therapeutic solutions. At Biocytogen, we provide AD disease models using both wild-type and drug-targeted humanized mouse models, such as B-hIL4/hIL4RA and B-hTSLP/hTSLPR mice. These models offer a reliable preclinical platform for evaluating novel therapies in both standard and human-relevant systems. Together, we’re advancing research toward more effective treatments for AD! Read more about Biocytogen’s AD models: https://lnkd.in/eixWkHvN #AtopicDermatitis #Biocytogen #DrugDiscovery #Immunology #PreclinicalModels #HumanizedMice #IL4 #TSLP?
?? Gene-ius Break Maryland: One Week to Go! ?? The countdown is on! Join us and KACTUS next Tuesday, March 4th for an evening of engaging conversations, mouthwatering food, refreshing drinks, and top-tier biotech networking. Don’t miss this chance to connect, unwind, and spark new collaborations—spots are filling up fast! We look forward to seeing you there! ??? Time: Tuesday, March 4th · 5:30 PM - 8:30 PM EST ?? Location: Clear Skies Meadery, 15201 Display Ct, Rockville, MD 20850 ?? RSVP here: https://lnkd.in/e2bZ5EkG
?? From Powerlifting to Power Deals: How Natalie Drives Innovation at Biocytogen! ?? Natalie Marchi PhD, RDN is a true powerhouse—both in biotech and in the gym! A Registered Dietitian Nutritionist, certified trainer, and former collegiate athlete, she’s no stranger to discipline and strength. From winning 1st place at APF Nationals with an 859.8 lb total to driving biotech partnerships, her determination is unmatched. Since joining Biocytogen in 2022, she’s taken on multiple roles, now leading strategic collaborations as part of the RenBiologics Licensing team. Her success comes from balancing science, strategy, and relationships. With expertise in project management and communication, she seamlessly connects innovation with industry needs. Her advice? Embrace challenges—they’re the key to growth! Whether in powerlifting or biotech, Natalie proves that real strength is about pushing boundaries and seizing opportunities! ???? Read more:?https://lnkd.in/e9B7KR66 #Biocytogen #WomenInSTEM #BiotechCareers #Powerlifting #BusinessDevelopment #Innovation
?? Unlocking the Potential of 4-1BB HCAbs in Cancer Immunotherapy ?? 4-1BB (CD137, TNFRSF9) is a key immune costimulatory receptor expressed on activated CD4+ and CD8+ T cells, NK cells, and regulatory T cells (Tregs), enhancing T cell activation, survival and tumor-specific memory responses. While 4-1BB holds great promise in cancer immunotherapy, the clinical use of 4-1BB monoclonal antibodies has been limited by liver toxicity. To improve safety, innovative approaches like bispecific antibodies and CAR-T therapies incorporating 4-1BB signaling are under development. At Biocytogen, we are advancing next-generation 4-1BB therapeutics with fully human heavy chain-only antibodies (HCAbs), developed using our RenNano? platform. These HCAbs, engineered into bispecific formats, offer high tissue penetration and low immunogenicity, paving the way for safer and more effective cancer treatments. Contact us to explore licensing and co-development opportunities! #Immunotherapy #CancerResearch #41BB #CD137 #Biocytogen #RenNano #BispecificAntibodies #CART #HCAb
?? Biotech is evolving faster than ever—what breakthrough excites you the most? ??? From gene editing & CRISPR rewriting DNA to AI revolutionizing drug discovery, the future of medicine is unfolding before our eyes. Immunotherapy is changing the way we fight diseases, while organoids & lab-grown tissues are bringing us closer to personalized treatments. Which of these cutting-edge advancements sparks your curiosity the most? Vote below and tell us why in the comments! ???? #Biotech #Innovation #CRISPR #Immunotherapy #AIDrugDiscovery #Organoids #FutureOfMedicine #ScienceRocks #Breakthroughs
此处无法显示此内容
在领英 APP 中访问此内容等
?? Biotech innovators, Gene-ius Break Maryland is here! ?? Join us on March 4th for an unforgettable evening filled with engaging conversations, mouthwatering food, refreshing drinks, and incredible networking opportunities with biotech’s brightest innovators! We’re excited to co-host this event with KACTUS, bringing together even more industry leaders for meaningful connections. Don’t miss your chance to connect, relax, and spark new collaborations. Spots are filling up fast—secure yours today! ?? ??? Time: Tuesday, March 4th · 5:30 PM - 8:30 PM EST ?? Location: Clear Skies Meadery, 15201 Display Ct, Rockville, MD 20850 ?? RSVP here: https://lnkd.in/e2bZ5EkG
?? Advancing Targeted Therapies for Atopic Dermatitis! ?? Atopic Dermatitis (AD) is a chronic inflammatory skin condition affecting 320 million adults worldwide. These patients endure intense itching, painful sores, and comorbidities like cardiovascular disease, depression, and sleep disturbances. Yet, for many, conventional topical treatments provide limited relief, underscoring the urgent need for more effective therapies. ?? Targeted antibody therapies are transforming AD treatment by blocking key inflammatory pathways involved in AD pathogenesis, such as OX40 and IL-4R. At Biocytogen, our RenMice? platform drives the discovery of high-affinity, high-specificity AD-related antibody assets. For example, our OX40 BpAb effectively blocks OX40L binding and activation, showing superior in vivo efficacy compared to benchmarks. ?? Contact us today to learn more about our assets and explore licensing and co-development opportunities! #AtopicDermatitis #Immunology #OX40 #IL4R #Biocytogen #AntibodyTherapeutics #DrugDiscovery #Inflammation #RenMice
?? Biocytogen at World ADC London 2025! ?? We’re thrilled to announce our partnership with World ADC London 2025 from March 3rd to 6th! This premier event brings together over 700 industry leaders to explore the latest advancements in antibody-drug conjugates (ADCs) and foster groundbreaking collaborations in biotechnology. Join us at Novotel London West to engage with key players and innovative biotech pioneers. Don't miss this opportunity to connect, learn, and shape the future of ADC development! ?? Date: March 3rd – 6th ?? Venue: Novotel London West, 1 Shortlands, London W6 8DR, UK #WorldADCLondon #ADC #Biocytogen #AntibodyTherapeutics #BiotechNetworking #DrugDiscovery